Clinical trial of MBX 1416 for Post-Bariatric Hypoglycemia beginsThe first participant has been dosed in MBX Biosciences’ Phase 1/2 clinical trial of MBX 1416, the company’s long-acting glucagon-like...
MBX Biosciences gains FDA clearance to study MBX 1416 for post-bariatric hypoglycaemiaMBX Biosciences, a clinical stage biopharmaceutical company developing Precision Endocrine Peptide (PEP) therapeutics to treat an array...
Tirzepatide found to reduce body weight regardless of duration of condition and BMI before treatment2 days ago